泛福舒胶囊治疗支气管哮喘患儿的临床研究  

Clinical trial of Fanfusu Capsules in the treatment of children with bronchial asthma

作　　者：钱东林 高翔 李翔翔 陆小芳 钱靖 沈振芳 QIAN Dong-lin;GAO Xiang;LI Xiang-xiang;LU Xiao-fang;QIAN Jing;SHEN Zhen-fang(Clinical Laboratory Suzhou Ninth People's Hospital,Suzhou 215200,Jiangsu Province,China;Department of Pediatrics,Suzhou Ninth People's Hospital,Suzhou 215200,Jiangsu Province,China)

机构地区：[1]苏州市第九人民医院检验科,江苏苏州215200 [2]苏州市第九人民医院儿科,江苏苏州215200

出　　处：《中国临床药理学杂志》2020年第21期3407-3409,3417,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨泛福舒胶囊在支气管哮喘患儿治疗中的价值及对外周血单个核细胞(PBMC)中磷脂酰肌醇3-激酶(PI3K)、核因子-кB(NF-кB)、信号传导及转录激活蛋白1(STAT1)水平的影响。方法根据入院顺序将纳入的支气管哮喘患儿随机分为2组:试验组52和对照组各53例。2组均用布地奈德混悬液的氧雾化吸入治疗,流量氧气速率为4~8 L·min-1,每天2次。同时,试验组给予口服泛福舒胶囊,每次7 mg,每天1次;2组均治疗3周。对比2组的临床疗效;酶联免疫吸附试验法测定嗜酸性阳离子蛋白(ECP),用自动血液分析仪检测嗜酸性粒细胞(EOS)计数,蛋白质印迹法检测PBMC中PI3K、NF-κB和STAT1蛋白表达。结果治疗后,试验组的总有效率为100.00%,高于对照组的86.79%,组间比较差异有统计学意义(P<0.05)。试验组和对照组的ECP分别为(9.21±2.54)和(11.26±3.01)μg·L-1;这2组的EOS分别为(0.34±0.10)和(0.40±0.12)109/L;这2组的PI3K蛋白表达分别为0.38±0.06和0.41±0.05;这2组的NF-кB蛋白表达分别为0.27±0.02和0.29±0.03;这2组的STAT1蛋白表达分别为0.36±0.04和0.39±0.04,上述指标:组间比较差异均有统计学意义(均P<0.05)。结论泛福舒联合布地奈德治疗支气管哮喘患儿能更有效的调节PBMC中PI3K、NF-кB、STAT1蛋白表达水平及外周血ECP、EOS水平,从而提高临床效果。Objective To explore the value of Fanfusu Capsules in the treatment of children with bronchial asthma and effect of phosphatidylinositol 3-kinase(PI3 K),nuclear factor-кB(NF-кB),signal transduction and activator of transcription 1(STAT1)levels in peripheral blood mononuclear cells(PBMC).Methods According to the order of admission,the children with bronchial asthma were randomly divided into 2 groups:52 in the treatment group and 53 in the control group.Both groups were treated with oxygen atomization inhalation of budesonide suspension at a flow rate of 4-8 L·min-1,twice a day.At the same time,the treatment group was given oral Fanfusu Capsules,7 mg each time,once a day;both groups were treated for 3 weeks.The clinical efficacy of the two groups was compared.The enzyme-linked immunosorbent assay was used to determine the eosinophilic cationic protein(ECP).The automatic blood analyzer was used to detect the eosinophil(EOS)count.The expression levels of the PI3 K,NF-κB and STAT1 proteins were detected by Western blot.Results After treatment,the total effective rate of the treatment group was 100.00%,higher than that of the control group 86.79%,and the difference between the groups was statistically significant(P<0.05).The ECP in treatment group and control group were(9.21±2.54)and(11.26±3.01)μg·L-1,respectively;the EOS of the two groups were(0.34±0.10)and(0.40±0.12)109/L,respectively;the PI3 K protein of the two groups were 0.38±0.06 and 0.41±0.05,respectively;the NF-кB protein of the two groups were 0.27±0.02 and 0.29±0.03,respectively;the STAT1 protein of the two groups were0.36±0.04 and 0.39±0.04,respectively.The differences of the above indicators between the groups were statistically significant(all P<0.05).Conclusion Fanfusu Capsules combined with budesonide in the treatment of children with bronchial asthma can more effectively regulate the expression levels of PI3 K,NF-кB,STAT1 protein in PBMC and the levels of ECP and EOS in peripheral blood,thereby improving the clinical effect.

关 键 词：泛福舒胶囊 支气管哮喘 磷脂酰肌醇3-激酶 核因子-КB 信号传导及转录激活蛋白1 

分 类 号：R97[医药卫生—药品]